Ovid Therapeutics
137 articles about Ovid Therapeutics
-
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
11/10/2021
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today provided a business update and reported corporate highlights and financial results for the quarter ended September 30, 2021.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
10/7/2021
Ovid Therapeutics Inc. today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.
-
Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Ovid Therapeutics Inc. today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8/16/2021
Ovid Therapeutics Inc. today reported financial results for the quarter ended June 30, 2021.
-
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
-
This week's announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech's advisory board.
-
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
7/8/2021
Ovid Therapeutics Inc. (NASDAQ: OVID) today announced appointments to its board of directors and leadership team as well as a realignment of its workforce to focus on early-stage development activities, including the build out of its neuroscience programs
-
Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
7/7/2021
Ovid Therapeutics Inc. today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET.
-
Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer– Broadened role enables deeper focus on the Company’s business strategy –
6/4/2021
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona has expanded his role to include Chief Financial Officer responsibilities
-
Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board
5/26/2021
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board.
-
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/13/2021
Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the quarter ended March 31, 2021 and provided an overview of the Company’s recent progress.
-
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
5/12/2021
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.
-
Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
4/20/2021
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board.
-
OVID Provides Update on OV101 Program and the Prioritization of its Resources
4/19/2021
Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome
-
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
3/30/2021
Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the closing of the Royalty, License and Termination agreement (the “Agreement”) under which Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935)
-
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
3/15/2021
Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing
-
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
3/3/2021
Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
-
Takeda will develop soticlestat, a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), as a potential treatment for developmental and epileptic encephalopathies.
-
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
12/16/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASD